ELECTRONIC BIOSCIENCES, INC. — Department of Health and Human Services SBIR Phase I: 172

Description

Project Summary At this point in timeit is generally understood and agreed upon that single molecule sequencingSMSis the future of genomicstranscriptomicsepigenomicsand epitranscriptomics due to its significant advantages over other technologies and methodsHoweverin order for these advantages to be fully realizedand for SMS to become thegold standardsequencing approachsignificant issues and hurdles must be solved and overcomeDuring this programElectronic BioSciencesIncEBSaims to demonstrate a completely new and enabling SMS method that will possess the ability to directly and correctly identify individual nucleotidesincluding chemically modified nucleotidesDuring this projectwe will both demonstrate the ability of this entirely new sequencing approach to sequence DNA with high accuracydirectly comparing the obtained accuracythroughputerror mechanisms and associated rates to other SMS approachesand correctly identifyand sequencemethylcytosinemCand its derivativesat the single molecule levelAt the conclusion of this Phase I projectwe will have successfully demonstrated an entirely new and dramatically improved SMS approachand reduced the associated risks involved with its full future commercial developmentsThere is a current need within the field of next generation sequencingNGSor so called third generation sequencingTGSfor newenabling instrumentation that is capable of high accuracydirectnative DNA sequencingincluding the ability to correctly identify canonical and modified baseshomopolymer stretchesand sequence repeatsThe entirely new SMS methodology that will be developed during this project will overcome known hurdles and limitations of currently available NGSTGSand SMS technologiesresulting in technology that is cost efficienthighly accurateeasy to setup and utilizecapable of de novo sequencing and modified base callingand yields highly simplistic data for easy analysis and post possessingThrough significant advancements made during this programthis resulting technology will revolutionize the use of the genome and epigenomeradically change standard Randamp D and clinical practicesand greatly advance clinical diagnosticsprognosticsand therapeutic decision making Project Narrative The novel single molecule sequencingSMStechnology developed during this project will enable highaccuracydirectnative DNA sequencingincluding the ability to correctly identify canonical and modified baseshomopolymer stretchesand sequence repeats via a cost efficient and easy to use methodologyThe impact of these advances in SMS will eventually enable wide scaleroutine clinical care and diagnostics toward advanced precision medicinenot just Randamp DThe performance and accessibility of such technology will transform the understanding and application of genomics and epigenomicsthe associated clinical practicesthat ability to provide precision clinical diagnosticsprognosticsand therapeutic decision making for improved public healthcare and wellbeing